Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Change in Cash (2020 - 2025)

Historic Change in Cash for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $21.8 million.

  • GeneDx Holdings' Change in Cash rose 110176.02% to $21.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.1 million, marking a year-over-year increase of 22948.72%. This contributed to the annual value of -$14.5 million for FY2024, which is 6156.24% up from last year.
  • GeneDx Holdings' Change in Cash amounted to $21.8 million in Q3 2025, which was up 110176.02% from -$25.6 million recorded in Q2 2025.
  • GeneDx Holdings' 5-year Change in Cash high stood at $424.8 million for Q3 2021, and its period low was -$93.3 million during Q3 2022.
  • For the 5-year period, GeneDx Holdings' Change in Cash averaged around -$1.2 million, with its median value being -$25.6 million (2025).
  • Data for GeneDx Holdings' Change in Cash shows a peak YoY increase of 3716796.72% (in 2021) and a maximum YoY decrease of 564563.38% (in 2021) over the last 5 years.
  • GeneDx Holdings' Change in Cash (Quarter) stood at -$60.7 million in 2021, then fell by 11.07% to -$67.4 million in 2022, then surged by 118.36% to $12.4 million in 2023, then soared by 120.67% to $27.3 million in 2024, then decreased by 20.03% to $21.8 million in 2025.
  • Its Change in Cash stands at $21.8 million for Q3 2025, versus -$25.6 million for Q2 2025 and $14.5 million for Q1 2025.